Skip to content

EVOLVING AZIMUTH IN MUSA CONTEXT

EVOLVING AZIMUTH IN MUSA CONTEXT

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07022067
Acronym
AZIMUSA
Enrollment
184
Registered
2025-06-15
Start date
2024-10-02
Completion date
2025-08-31
Last updated
2025-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Pressure, Heart Failure, Telemonitoring, Weight Change

Brief summary

Non-pharmacological, randomized, nonprofit medical device intervention. The study aims to identify the positive impacts (co-creation), and negative impacts (co-destruction), resulting from the use of telemedicine, and, in particular, the telemonitoring service for patients with heart failure

Detailed description

The patient diagnosed with heart failure is randomized to either the experimental or control arm. The patient in the experimental arm downloads a telemonitoring application where they enter their pressure and body weight data, which is revised by the hospital team via a platform. Patients from both arms complete a questionnaire during enrollment and during two follow-ups (3 months and 6 months) to examine various dimensions.

Interventions

DEVICETelemonitoring app

periodic measurement of blood pressure and body weight

Sponsors

ASST Grande Ospedale Metropolitano Niguarda
CollaboratorOTHER
University of Milan
CollaboratorOTHER
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Have been diagnosed with chronic CS according to the ESC guidelines; * Over 18 years of age; * Patients admitted to hospital or with access to first aid within the last year; * Smartphome that meets the digital requirements (ie Android or iOS able to download and use the application); * Wi-Fi or 3G coverage at home; * Ability to give written informed consent.

Exclusion criteria

* Severe psychiatric disorder * Inability to use portable technologies * Patients unable to use the equipment provided * Patients who deny consent to study participation

Design outcomes

Primary

MeasureTime frameDescription
PAM13-I6 monthsThe Patient Activation Measure (PAM13-I) is a brief, validated instrument that assesses patient knowledge, skills, and confidence for disease self-management. It consists of 13 items on a Likert scale. According to the American version of PAM 13, each item has five response categories with scores from 1 to 5: (1) Strongly Disagree, (2) Disagree, (3) Agree, (4) Strongly Agree and (5) Not Applicable. The instrument design reflects the four stages of activation in a progressing difficulty of the items: level 1 (patients believe that their role is important: items 1 and 2), level 2 (patients have confidence and knowledge to take action: items 3-8) level 3 (taking action: items 9-11) and level 4 (staying on course under stress: items 12 and 13).

Countries

Italy

Contacts

Primary ContactStefano Prof. Carugo
stefano.carugo@policlinico.mi.it+390255033532

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026